Artwork

Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

To RNase or Not to RNase: That Is the Question

14:05
 
Share
 

Manage episode 404548185 series 1099819
Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity.

Read the related paper in LSM - https://doi.org/10.1136/lupus-2023-001113

  continue reading

54 episodes

Artwork
iconShare
 
Manage episode 404548185 series 1099819
Content provided by BMJ Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BMJ Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with moderate to severe cutaneous disease activity were administered RSLV-132 over a span of six months. Disease activity was evaluated using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). These findings suggest that RNAse therapy may be effective in patients with higher disease activity.

Read the related paper in LSM - https://doi.org/10.1136/lupus-2023-001113

  continue reading

54 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide